Silent Symposium: combination therapies for treating MS

The following two presentations are from last week’s ABN meeting in Birmingham on the topic of the need for combination therapies. It is clear that based on the current efficacy profile of DMTs if we are going to make a difference to people with MS we are going to need to build a sandwich of treatments targeting different pathogenic, including premature ageing.

I gave these presentations as back-to-back talks on the silent symposium platform. A silent symposium is when you speak softly into a microphone and your audience listens to you wearing headsets. The idea is to allow the symposium to occur in the same venue as the posters and exhibitions and make too much noise; not too dissimilar to a silent disco. 

Part 1

Part 2


About the author

Prof G

Professor of Neurology, Barts & The London. MS & Preventive Neurology thinker, blogger, runner, vegetable gardener, husband, father, cook and wine & food lover.


  • Excellent presentations. As ever with this disease, it's the issue of timescale. When are we going to have neuroprotective, remyelinating and neurorestorative treatments available for patients?

  • I can see, looking at the first slideshow, how hard It is to design a trial for combination therapies. I'm looking at the moment quite hard at slide 11 and pondering whether there is fundamental issue with the design of the trial.

    I've just given up poring because my mind started to go round and round.

    If my understanding is right then the randomisation in the Ponesimod trial was amongst participants who were already being treated with DMF.

    How can you tell at the endpoint any effects observed are not due to the DMF?

  • This, in terms of cumulative side effects and the limits of what the human frame can withstand, totally unrealistic.

By Prof G



Recent Posts

Recent Comments